卡培他滨个体化治疗结直肠癌研究进展

发布时间：2018-03-30 04:13

本文选题：卡培他滨　切入点：药代动力学和药效学　出处：《中国医院药学杂志》2017年09期

【摘要】：结直肠癌是最常见的癌症之一,每年可造成数十万人死亡,死亡率和发病率都呈逐年上升趋势。卡培他滨用于治疗结直肠癌已有十年的时间,其更好的疗效和用药依从性使其成为一种治疗结直肠癌的主要药物,但其同样有着不可忽视的毒副作用。研究发现卡培他滨疗效和毒副作用同其代谢基因的多态性有极大的关联,基因多态可在一定程度上解释其疗效和毒副作用的差异性。随着精准医疗的发展,制定精准高效的治疗策略,在基于分子生物学研究进展的基础上开展抗肿瘤药物的"个体化"治疗方案制订,是抗肿瘤药物治疗迫切需要研究的内容。卡培他滨药代动力学和药效学、药物相互作用、代谢相关基因多态性和临床应用的综述可以为卡培他滨个体化药物治疗方案的制订提供参考。
[Abstract]:Colorectal cancer is one of the most common cancers, causing hundreds of thousands of deaths every year and increasing mortality and morbidity. Capecitabine has been used to treat colorectal cancer for 10 years. Its better efficacy and compliance make it a major drug in the treatment of colorectal cancer. But it also has side effects that can't be ignored. Studies have found that capecitabine's efficacy and side effects are strongly associated with its metabolic gene polymorphisms. Gene polymorphism can explain to some extent the difference between efficacy and side effects. With the development of precision medicine, the development of precise and efficient treatment strategy, On the basis of the progress in molecular biology, the development of "individualized" treatment of antitumor drugs is an urgent need for study in the treatment of antitumor drugs, and the pharmacokinetics and pharmacodynamics of capecitabine, drug interaction, and pharmacokinetics, pharmacokinetics, pharmacodynamics, and pharmacodynamics of capecitabine, A review of metabolic gene polymorphisms and clinical applications may provide a reference for the formulation of capecitabine individualized drug therapy.
【作者单位】：第二军医大学长征医院药材科;中国人民解放军第97医院药剂科;
【基金】：国际科技合作与交流专项(编号:2015DFA31810)
【分类号】：R735.34

【相似文献】